
In July, Newsweek ran a story with a headline I could have written myself: “Peptides Are the New Longevity Craze. Safety Data Tells a Different Story,” by Melissa Fleur Afshar, July 30.
The reporter asked me. The story ran without my answer. I have already written about what a peptide is, about how we run a peptide protocol, and about what I look for on a vial. This post is about the one thing that headline promised and the marketing never mentions: the data.
What Newsweek’s Sources Said
The piece put the wellness industry at $6.8 trillion and peptide searches at 10.1 million a month in January, five times the 2020 number. It was built around a July 23 meeting of the FDA’s Pharmacy Compounding Advisory Committee on whether at least four previously banned peptides could be compounded on prescription, after a February announcement that roughly 14 of 19 restricted peptides could come off the list.
The sharpest line came from Mansoor Amiji, a professor of pharmaceutical sciences at Northeastern: “Except for GLP-1 agonists by Eli Lilly and Novo, and other FDA-approved peptides, there are no preclinical or clinical studies showing safety and effectiveness of these ‘hyped’ peptides.”
His colleague Steve Kates said the approval bar, efficacy, manufacturing validation and toxicology, has not been cleared: “These products haven’t gone through any of that.”
The clinicians in the story were not against access. Karthik Achari of PepMD called a regulated pathway “categorically safer than a grey market,” and added the line I wish every patient would read: “Being authorized to prescribe a peptide and being qualified to prescribe one are two different things, and nothing in the current system tells you which is which.”
I agree with all of them. They are answering different questions.
Four Categories, Four Different Amounts of Data
Here is the version I sent the reporter, in the plainest terms I have.
“A peptide is a size designation, nothing else. Insulin is a peptide, and the contents of the vial someone ordered at two in the morning from an online store is also a peptide. Treating those two things as one story is how the public ended up this confused.”
So split the story. This is the table I draw for patients.
| Category | What the safety data shows | What it does not show |
|---|---|---|
| FDA-approved peptides (insulin, the GLP-1s such as semaglutide and tirzepatide) | Full clinical trials, a label, dosing, known side effects, adverse-event reporting | Nothing about the wellness vial sold under the same word |
| Topical cosmetic peptides (copper and signal peptides in serums) | Lab studies on collagen synthesis; a few small trials with modest smoothing of fine lines over months | Much of the research is company-funded, as Newsweek’s own skin-care source noted; delivery through intact skin is limited |
| Compounded peptides on prescription from a 503A or 503B pharmacy | Sterility testing, a verified dose and purity on the label, a physician in the loop | That the peptide works; manufacturing standards are not efficacy trials |
| “Research use only” vials bought online | Nothing | Contents, dose, sterility, or who made it |
The top row is where the trials are. Every row below it borrows the top row’s reputation.
The Topical Story Is Mostly a Quiet One
“In short, the science is good, not great.”
“Thus, a peptide is a reasonable addition to a product where a sunscreen and a retinoid are doing the real work. It is not a replacement for either one.”
The risk with a serum is rarely the serum. It is the plan: a patient who skips sunscreen because the label says collagen. That is the quiet harm, and no advisory committee is going to meet about it.
The Injectable Story Is Where the Data Runs Out
“Very few of them know how little human research is available on these compounds, know that most dosage regimens have been picked up from bodybuilding forums, or know that the vial is coming from an overseas research-chemical company, with no guarantee as to contents, purity or whether it is a sterile preparation.”
“I have seen and operated on patients with abscesses as well as infected lesions at injection sites that stem from these supplies.”
That is the safety data I own: not a trial, a drain and a culture. The common denominator, from my MDLinx answers in September:
“I have seen many cases like this, so this is not an isolated case. And the common denominator in all these cases has been that the substances or the peptides have been acquired through unlicensed sources. To avoid this, I recommend obtaining all peptides from a certified pharmacy through your physician.”
What the FDA Decision Does and Does Not Change
This is the part of the Newsweek story people will get wrong, and I said so to the reporter.
“Allowing a pharmacy to compound it means a pharmacy can make it. Allowing them to make it does not mean it will work. That will likely lead many readers to think the first fact answers the second, which it does not.”
“The big risk is that people read the news and think a scientist gave their blessing simply because it became more available.”
The HHS press secretary told Newsweek the final rule “may include all, some, or none of the substances proposed for inclusion on the 503A Bulks List.” The policy has kept moving since July, and I will come back to it. The principle has not moved: a pharmacy shelf is a manufacturing standard, not a clinical trial.
How My Practice Screens and Monitors
At the Med Spa, nothing injectable comes from an unknown source, and nobody starts a protocol on a hunch. From the protocol answers I gave Peptides Business Wire:
“Patients are referred for comprehensive baseline laboratory testing prior to initiating therapy. Baseline laboratory evaluations include assessment of liver and kidney function through a CMP.”
“We put them on a protocol. They visit monthly, get bloodwork done every 3 to 6 months and we titrate their medication as we go, over a period of years.”
And in the surgical practice the question is now routine:
“I am now asking my patients about peptide use before surgery exactly how I would ask them about supplements. When it comes from an online research chemical supplier, neither the patient nor I knows what is inside the bottle.”
The surgical side of that, what an unlabeled vial does to an operation, is on Agullo Plastic Surgery. The shorter read on why the regulators and the researchers are both right is on Dr. WorldWide.
Why Choose Dr. Agullo
I am certified by the American Board of Plastic Surgery and the American Board of Surgery, completed my plastic surgery fellowship at the Mayo Clinic, and serve as Clinical Associate Professor of Plastic Surgery at Texas Tech University Health Sciences Center. I sit on the editorial boards of Aesthetic Plastic Surgery and Plastic and Reconstructive Surgery Global Open, and Castle Connolly has listed me as a Top Doctor every year from 2014 through 2026. The Med Spa at Southwest Plastic Surgery runs its peptide and medically supervised GLP-1 programs from licensed pharmacies, with labs, under a provider.
Ready to Talk?
If you are already injecting something, bring the vial to your appointment and we will read the label together. Call (915) 590-7900, text 1-866-814-0038, or book online at agulloplasticsurgery.com/appointments. #StayBeautiful
Find me at @RealDrWorldWide on Instagram, TikTok, and Snapchat, @Agullo on X, or @AgulloPlasticSurgery on Facebook.